Aurobindo, MSN Fall To US Nuplazid Patent Expiring In August 2038
Formulation Patent Ruled Valid; Aurobindo ANDA Infringes, MSN Already Admitted
Acadia’s Nuplazid for hallucinations and delusions associated with Parkinson’s disease psychosis is looking safe from generic competition – for now – until well into the next decade, following a favorable infringement and validity decision by a US district court.
